The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial

2.50
Hdl Handle:
http://hdl.handle.net/11287/593979
Title:
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial
Authors:
Paggiaro, P.; Halpin, David M; Buhl, R.; Engel, M.; Zubek, V. B.; Blahova, Z.; Moroni-Zentgraf, P.; Pizzichini, E.
Abstract:
BACKGROUND: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated efficacy in patients with asthma who were symptomatic despite treatment with medium- to high-dose inhaled corticosteroids (ICS). OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of once-daily tiotropium Respimat (5 mug or 2.5 mug), compared with placebo Respimat, as add-on therapy to low- to medium-dose ICS for adults with symptomatic asthma. METHODS: A phase III, double-blind, placebo-controlled trial was conducted (NCT01316380). Adults with symptomatic asthma receiving low- to medium-dose ICS (200-400 mug budesonide or equivalent dose) and a pre-bronchodilator forced expiratory volume in 1 second (FEV1) >/=60% and </=90% of predicted normal were randomized to 12 weeks of treatment with once-daily tiotropium Respimat 5 mug or 2.5 mug, or placebo Respimat, as add-on therapy to ICS. The primary endpoint was peak FEV1(0-3h) response. RESULTS: In total, 464 patients were randomized (61% female; mean age 43 years; mean baseline FEV1 78% of predicted normal). After 12 weeks, both tiotropium Respimat doses were superior to placebo (adjusted mean difference from placebo: 5 mug, 128 mL; 2.5 mug, 159 mL; both P < .001). Both doses of tiotropium Respimat were also superior to placebo with regard to the secondary endpoints of adjusted mean trough FEV1 and FEV1 area under the curve(0-3h) responses, and the other endpoints of morning and evening peak expiratory flow. Adverse events were comparable across the treatment groups. CONCLUSIONS: Once-daily tiotropium Respimat add-on therapy to low- to medium-dose ICS in adults with symptomatic asthma is an efficacious bronchodilator, and its safety and tolerability are comparable with those of placebo Respimat.
Citation:
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104-13
Publisher:
Elsevier
Journal:
The journal of allergy and clinical immunology. In practice
Issue Date:
7-Nov-2015
URI:
http://hdl.handle.net/11287/593979
DOI:
10.1016/j.jaip.2015.08.017
PubMed ID:
26563670
Additional Links:
http://www.sciencedirect.com/science/article/pii/S2213219815005206
Note:
This article is available via Open Access. Please click on the 'Additional Link' above to access the full-text.
Type:
Journal Article
Language:
Eng
ISSN:
2213-2201
Appears in Collections:
2015 RD&E publications; Respiratory Medicine; Respiratory Medicine

Full metadata record

DC FieldValue Language
dc.contributor.authorPaggiaro, P.en
dc.contributor.authorHalpin, David Men
dc.contributor.authorBuhl, R.en
dc.contributor.authorEngel, M.en
dc.contributor.authorZubek, V. B.en
dc.contributor.authorBlahova, Z.en
dc.contributor.authorMoroni-Zentgraf, P.en
dc.contributor.authorPizzichini, E.en
dc.date.accessioned2016-01-19T12:38:13Zen
dc.date.available2016-01-19T12:38:13Zen
dc.date.issued2015-11-07en
dc.identifier.citationJ Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104-13en
dc.identifier.issn2213-2201en
dc.identifier.pmid26563670en
dc.identifier.doi10.1016/j.jaip.2015.08.017en
dc.identifier.urihttp://hdl.handle.net/11287/593979en
dc.description.abstractBACKGROUND: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated efficacy in patients with asthma who were symptomatic despite treatment with medium- to high-dose inhaled corticosteroids (ICS). OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of once-daily tiotropium Respimat (5 mug or 2.5 mug), compared with placebo Respimat, as add-on therapy to low- to medium-dose ICS for adults with symptomatic asthma. METHODS: A phase III, double-blind, placebo-controlled trial was conducted (NCT01316380). Adults with symptomatic asthma receiving low- to medium-dose ICS (200-400 mug budesonide or equivalent dose) and a pre-bronchodilator forced expiratory volume in 1 second (FEV1) >/=60% and </=90% of predicted normal were randomized to 12 weeks of treatment with once-daily tiotropium Respimat 5 mug or 2.5 mug, or placebo Respimat, as add-on therapy to ICS. The primary endpoint was peak FEV1(0-3h) response. RESULTS: In total, 464 patients were randomized (61% female; mean age 43 years; mean baseline FEV1 78% of predicted normal). After 12 weeks, both tiotropium Respimat doses were superior to placebo (adjusted mean difference from placebo: 5 mug, 128 mL; 2.5 mug, 159 mL; both P < .001). Both doses of tiotropium Respimat were also superior to placebo with regard to the secondary endpoints of adjusted mean trough FEV1 and FEV1 area under the curve(0-3h) responses, and the other endpoints of morning and evening peak expiratory flow. Adverse events were comparable across the treatment groups. CONCLUSIONS: Once-daily tiotropium Respimat add-on therapy to low- to medium-dose ICS in adults with symptomatic asthma is an efficacious bronchodilator, and its safety and tolerability are comparable with those of placebo Respimat.en
dc.language.isoEngen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S2213219815005206en
dc.titleThe Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trialen
dc.typeJournal Articleen
dc.identifier.journalThe journal of allergy and clinical immunology. In practiceen
dc.description.noteThis article is available via Open Access. Please click on the 'Additional Link' above to access the full-text.en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.